Chronic Pancreatitis (CP) Global Market Report 2025

The chronic pancreatitis (CP) market size has grown strongly in recent years. It will grow from $4.91 billion in 2024 to $5.25 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to the increasing prevalence of alcohol consumption, the rising incidence of smoking, genetic predisposition and family history, growing awareness of pancreatic diseases, the rising cases of diabetes linked to pancreatitis, increasing healthcare spending, and improved access to healthcare services.

The chronic pancreatitis (CP) market size is expected to see strong growth in the next few years. It will grow to $6.72 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the rising geriatric population, increasing demand for enzyme replacement therapies, growing awareness of early diagnosis, expansion of healthcare infrastructure in emerging markets, development of novel pain management therapies, and increasing research and clinical trials for pancreatitis treatment. Major trends include the use of artificial intelligence in diagnostic imaging, advancements in minimally invasive surgical techniques, the adoption of wearables for continuous health monitoring, next-generation sequencing for genetic testing, integration of machine learning in disease progression tracking, and the development of smart diagnostic tools.

The rising consumption of alcohol is anticipated to drive the growth of the chronic pancreatitis market in the coming years. Alcohol consumption involves the intake of ethanol-containing beverages, often for recreational, social, or cultural reasons, but excessive use can lead to dependency and health complications. Factors such as increasing social acceptance, urbanization, evolving lifestyles, and stress management practices, particularly among younger demographics, contribute to the growing consumption of alcohol. Alcohol-induced chronic pancreatitis occurs due to inflammation and damage to pancreatic cells, resulting in fibrosis, ductal blockages, and long-term dysfunction caused by toxic metabolic byproducts. For example, in December 2023, a publication by Kirin Holdings Company Limited, a Japan-based beer and beverage holding company, reported that total global beer consumption in 2022 increased by approximately 5.4 million kiloliters (equivalent to around 8.5 billion 633ml bottles) compared to 2021, reaching around 192.1 million kiloliters. This 2.9% increase was attributed to the easing of COVID-19’s impact, amounting to roughly 303.5 billion 633ml bottles. As a result, the rising consumption of alcohol is fueling the expansion of the chronic pancreatitis market.

Leading companies in the chronic pancreatitis market are investing in technological advancements such as enzyme replacement therapy to address exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis. Enzyme replacement therapy involves administering oral pancreatic enzymes to support digestion in individuals with impaired pancreatic function. For instance, in July 2023, First Wave BioPharma Inc., a US-based clinical-stage biopharmaceutical company, announced results from the Phase 2 SPAN clinical trial evaluating an advanced enteric microgranule delivery formulation of adrulipase for treating EPI in patients with cystic fibrosis (CF) and chronic pancreatitis. Adrulipase, a recombinant lipase enzyme derived from Yarrowia lipolytica yeast, is administered as an oral, non-systemic biologic capsule designed to break down fat molecules in the digestive tract of EPI patients, enabling nutrient absorption.

In March 2023, CalciMedica Inc., a US-based clinical-stage biopharmaceutical company, merged with Graybug Vision Inc. for an undisclosed amount. This merger, structured as a reverse transaction, strengthens CalciMedica’s efforts in developing therapies for life-threatening inflammatory diseases. Graybug Vision Inc. is a US-based clinical-stage biopharmaceutical company focused on advancing treatments for severe inflammatory diseases, including pancreatitis.

Major players in the chronic pancreatitis (CP) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy's Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, and Akron Biotech.

North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in chronic pancreatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic pancreatitis (CP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic pancreatitis (CP) is a persistent, progressive inflammatory disorder of the pancreas that leads to irreversible structural and functional damage. It is characterized by ongoing inflammation, fibrosis (scarring), and the gradual loss of the pancreas's ability to produce digestive enzymes and hormones such as insulin.

The primary treatment options for chronic pancreatitis include analgesics, artificial digestive enzymes, protein supplements, steroids, antibiotics, and others. Analgesics help manage pain, a common symptom of the condition. Diagnosis methods include computed tomography (CT) scans, magnetic resonance cholangiopancreatography, ultrasound sonography, and others. The routes of administration for treatments are oral and parenteral, with end users including hospitals, home care, and other healthcare providers.

The chronic pancreatitis (CP) market research report is one of a series of new reports that provides chronic pancreatitis (CP) market statistics, including chronic pancreatitis (CP) industry global market size, regional shares, competitors with a chronic pancreatitis (CP) market share, detailed chronic pancreatitis (CP) market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pancreatitis (CP) industry. This chronic pancreatitis (CP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic pancreatitis market consists of revenues earned by entities by providing services such as diagnostic imaging, endoscopic procedures, pain management, nutritional counseling, and telemedicine services for the diagnosis and management of chronic pancreatitis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pancreatitis market also includes sales of enzyme replacement therapies, pain management drugs, anti-inflammatory treatments, biologics, stem cell therapies, and surgical interventions, as well as diagnostic tools such as imaging and laboratory tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.